Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and DDI of CG-651 (Polmacoxib + Pregabalin) in Healthy Volunteers
NCT05370716Phase 1Completed
- Sponsor
- Crystal Genomics
- Start
- Nov 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of polmacoxib and pregabalin in neuropathic pain (3 arms), sponsored by Crystal Genomics. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve and 1 more. Started Nov 2019; status: completed.
02
Drugs
polmacoxibpregabalin
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT05370716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05370716.